The former, developed by the Center for Genetic Engineering and Biotechnology (CIGB), already passed Phase I of studies in humans for solid tumors in different locations some seven years ago with encouraging results, according to the director of business development and project management of the CIGB, Rolando Paez.
At present, he told Prensa Latina during the working sessions of the BioHabana 2022 International Congress that one percent of patients who received the drug are still alive, despite the fact that at that time some of them were in a terminal state and had no therapeutic treatment.
Now the second phase of clinical trials is being completed and a third phase is being prepared to use it in ovarian and other malignant tumors, he added.
This project was included as part of a contract with a CIGB joint venture in China, in order to further develop it in that market, while we look for new international partners, he added.
On the other hand, CIMAvax-EGF, designed to treat lung cancer, is being studied at the Roswell Park Institute in New York, in the United States.
According to statements made by Mary Reid, director of Collaborative Research and Associate Professor of Oncology, this scientific center is the only place in the United States that is currently using this vaccine for research purposes.